The global cholera vaccines market is a growing market owing to the rising prevalence of cholera disease globally. Cholera is an infectious bacterial disease caused by Vibrio cholera bacteria found in contaminated food or water. The common symptoms of cholera include diarrhea, vomiting, and leg cramps. Oral cholera vaccines help in developing antibodies that protect against cholera infection for 1-3 years. The global cholera vaccines market is dominated by Dukoral and Shanchol vaccines that are administered orally using drops or capsules.

The global cholera vaccines market is estimated to be valued at US$ 82.5 MN in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the global cholera vaccines market are Sanofi, Biovac.co.za., EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD. The major players are focusing on developing improved oral vaccines with low dosing, longer duration of protection, and thermostability for easy global access. Some of the key opportunities in the market include developing combination vaccines for cholera with other enteric diseases and vaccine development targeting specific serotypes of Vibrio cholerae bacteria. Advancements in conjugation technologies, antigen design, and adjuvant development are expected to yield more effective cholera vaccines.

Market drivers

The key driver boosting Cholera Vaccines Market Growth is rising incidents of cholera outbreaks globally especially in low and middle-income countries with lack of clean water and sanitation. As per WHO, there are an estimated 1.3 to 4 million cases of cholera, and 21,000 to 143,000 deaths globally due to cholera every year. Cholera being a vaccine-preventable disease, increasing vaccination drives especially in endemic regions is expected to significantly drive the adoption of oral cholera vaccines. Other drivers include supportive government initiatives and funding to improve sanitation and rollout vaccination programs.

Current challenges in the Global Cholera Vaccines Market:

The Global Cholera Vaccines Market is currently facing challenges due to uneven distribution of vaccines across regions, as cholera outbreaks occur irregularly. While effective cholera vaccines exist, proper funding must be secured and distribution plans established to ensure refugees and communities at risk can access vaccines. Building public trust in vaccination programs also requires addressing misinformation and addressing safety concerns that discouragetake-up of available immunization options. Overall, coordinated global efforts are needed to strengthen vaccine supply chains and promotion.

SWOT Analysis

Strength: Effective vaccines like Dukoral provide protection for 3 years. Combination oral and injectable vaccines offer flexibility.

Weakness: Vaccines have limited shelf life requiring cold chain during transport. Funding constraints can limit distribution especially during outbreaks.

Opportunity: Potential for approvals of additional vaccines like Euvichol and newer formulations. Growing focus on immunization programs in high risk areas.

Threats: Sustained vaccine hesitancy and resistance in some communities. Potential for vaccine stockouts if funding is inadequate.

The Global Cholera Vaccines Market is concentrated in regions with significant outbreaks and refugee crises in terms of value. Countries in Asia and Africa account for over 90% of the market currently led by India which experiences regular outbreaks. The market is also gaining presence in the Middle East due to humanitarian crises displacing vulnerable populations in Syria and Yemen.

The fastest growing region for the Global Cholera Vaccines Market will be Africa through 2031. Factors like rapid urbanization, conflicts, and natural disasters are increasing risk of cholera outbreaks across the region. Countries like Democratic Republic of Congo and South Sudan face recurrent epidemics necessitating strengthened immunization programs relying on cholera vaccines. Multilateral initiatives and local health authorities improving vaccination access will support continued growth in Africa.

*Note:
1.  Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it